Asterias Biotherapeutics is a development stage biotechnology company focusing in regenerative medicine. We are developing therapeutics based on two different platform technologies: dendritic cell cancer immunotherapy and pluripotent stem cells. Near term, we are leveraging these platforms to develop treatments to address significant unmet medical needs in neurology and oncology. These mature programs are focused on de-risked indications and are supported by robust proof-of-concept pre-clinical and clinical data. Our three therapeutic programs include:
- AST-VAC1 is an autologous immunotherapy treatment for Acute Myeloid Leukemia (AML) that has demonstrated improvement in long-term remission in a phase 2 trial. We are currently planning a phase 3 pivotal trial for accelerated approval in patients >60 years of age.
- AST-OPC1 are a neural cell type, which we manufacture from our pluripotent stem cell platform targeting spinal cord injury. A phase 1/2a trial is ongoing.
- AST-VAC2 is an allogeneic immunotherapy manufactured from our pluripotent stem cell platform that could have broad oncology applications. We are planning a phase 1 clinical trial in non-small cell lung cancer

We are a consolidated subsidiary of the BioTime family of companies, and are traded on the NYSE MKT under the ticker symbol AST.